Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liora M Schultz

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Cell|December 15, 2018
Organoid Modeling of the Tumor Immune MicroenvironmentJames T Neal, Xingnan Li, Junjie Zhu, et al.
Blood Advances|September 30, 2025
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucelLauren E Appell, Christina Baggott, Khanh Nguyen, et al.
Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.
Frontiers in Immunology|November 15, 2023
Mediport use as an acceptable standard for CAR T cell infusionMaya Eylon, Snehit Prabhu, Samuel John, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 29, 2024
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Cell|December 15, 2018
Organoid Modeling of the Tumor Immune MicroenvironmentJames T Neal, Xingnan Li, Junjie Zhu, et al.
Blood Advances|September 30, 2025
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucelLauren E Appell, Christina Baggott, Khanh Nguyen, et al.
Blood Advances|July 21, 2025
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecelSwati Naik, Subodh Selukar, Aimee C Talleur, et al.
Frontiers in Immunology|November 15, 2023
Mediport use as an acceptable standard for CAR T cell infusionMaya Eylon, Snehit Prabhu, Samuel John, et al.
Nature|February 7, 2022
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomasRobbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, et al.
Blood Advances|March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Liora M Schultz, Soyang Kwon, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Nature|November 29, 2024
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M<sup>+</sup> diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Pageof 4